At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
In Brief
A Phase 3 clinical trial evaluating Denosumab for Charcot Joint of Foot. Completed, enrolled 7 participants across 1 site.
Detailed Summary
Charcot neuroarthropathy (CN) is a debilitating disease primarily affecting poorly controlled diabetic patients with peripheral neuropathy. The consequences of CN include ulcerations of the foot and ankle, osteomyelitis, and severe musculoskeletal deformity. These consequences frequently lead to below-knee amputation of the affected limb. Currently treatment options are limited, and no pharmaceutical treatment has been efficacious in the medical literature. The purpose of this pilot study is to investigate the potential of the medication denosumab for acute stage Charcot neuroarthropathy.
Study Details
Timeline
Interventions
Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.